BHST (BioHarvest Sciences) LT-Debt-to-Total-Asset: 0.24 (As of Mar. 2026)

What is BioHarvest Sciences LT-Debt-to-Total-Asset?

BioHarvest Sciences BHST +0.72% 63 LT-Debt-to-Total-Asset is 0.24 as of Mar. 2026. GuruFocus rates BHST with a GF Score™ of 63/100 and a GF Value™ of $8.57 (Possible Value Trap). The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. BioHarvest Sciences's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.24.

BioHarvest Sciences's long-term debt to total assets ratio declined from Mar. 2025 (0.32) to Mar. 2026 (0.24). It may suggest that BioHarvest Sciences is progressively becoming less dependent on debt to grow their business.

BioHarvest Sciences (NAS:BHST) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

BioHarvest Sciences LT-Debt-to-Total-Asset Related Terms

BioHarvest Sciences LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for BioHarvest Sciences's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioHarvest Sciences LT-Debt-to-Total-Asset Chart

BioHarvest Sciences Annual Data

Trend

Apr16

Apr17

Apr18

Apr19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.22

0.18

0.10

0.37

0.26

BioHarvest Sciences Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.32	0.54	0.35	0.26	0.24

63GF Score

BioHarvest Sciences Inc BHST

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

BioHarvest Sciences LT-Debt-to-Total-Asset Calculation

BioHarvest Sciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	12.55	/	47.665
	=	0.26

BioHarvest Sciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	11.037	/	45.558
	=	0.24

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.24 mean?

BioHarvest Sciences (BHST) has a LT-Debt-to-Total-Asset of 0.24 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on BioHarvest Sciences and its competitors.

Is BioHarvest Sciences' LT-Debt-to-Total-Asset too high?

BioHarvest Sciences' current LT-Debt-to-Total-Asset is 0.24. Overall, BioHarvest Sciences has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does BioHarvest Sciences' LT-Debt-to-Total-Asset compare to BRID and BOF?

BioHarvest Sciences' LT-Debt-to-Total-Asset of 0.24 can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Consumer Packaged Goods company?

A good LT-Debt-to-Total-Asset depends on the Consumer Packaged Goods industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on BioHarvest Sciences and its competitors. BioHarvest Sciences's current LT-Debt-to-Total-Asset is 0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is BioHarvest Sciences stock overvalued right now?

Based on GuruFocus' analysis, BioHarvest Sciences (BHST) is currently considered Possible Value Trap. The stock's GF Value™ is $8.57, compared to a current price of $2.79 — trading 67.4% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.24. BioHarvest Sciences' overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For BioHarvest Sciences (BHST), the current LT-Debt-to-Total-Asset is 0.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioHarvest Sciences (BHST) Overvalued in 2026?

Based on GuruFocus' analysis, BioHarvest Sciences stock appears to be undervalued. The current stock price of $2.79 is trading 67.4% below its estimated GF Value™ of $8.57. GuruFocus considers BioHarvest Sciences to be Possible Value Trap.

Key valuation signals for BHST:

LT-Debt-to-Total-Asset: 0.24
GF Value™: $8.57 vs. price of $2.79 (67.4% below fair value)
GF Score™: 63/100 with 4 warning signs

No single metric tells the full story. See the BHST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioHarvest Sciences Business Description

Industry Consumer Defensive Consumer Packaged Goods

Comparable Companies BRID BOF BFNH LSF GWLL HAIN CLNN SRXH DDC LFVN XSWX:NESN XPAR:BN BOG:NUTRESA TSE:2802 NSE:NESTLEIND SHSE:603288 KHC SHSE:600887 GIS SZSE:300999

Other Exchanges 8MV0:Germany

Address 1140-625 Howe Street, Vancouver, BC, CAN, V6C 2T6

Website https://www.bioharvest.com

BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. The Company has two operating segments or business units: the Products business unit and the CDMO Services business unit. In identifying these operating segments, management generally follows the Company's service lines representing its main products and services. The Products Business Unit - Nutraceuticals: Research, development, manufacturing, marketing and sales of science-based health and wellness nutraceutical solutions which are manufactured and sold as dietary supplements, functional food and beverages. The CDMO Services Business Unit - comprising a Contract Development and Manufacturing Operation that offers pharmaceuticals, cosmeceuticals, nutraceuticals, and nutritions.

63GF Score

Get the complete analysis for BHST

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.79

Price

$8.57

GF Value

View BHST Analysis

See LT-Debt-to-Total-Asset data for all stocks →